维莫非尼联合利妥昔单抗成功治疗复发性毛细胞白血病1例

A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia

  • 摘要: 毛细胞白血病(HCL)是一种在临床上较为罕见的血液系统恶性肿瘤。本文报道了1例复发性HCL患者的诊疗过程。患者为51岁女性,于2013年6月确诊为HCL,并接受克拉屈滨单药化疗,化疗后评估疗效为部分缓解。2023年11月出现胸闷、憋气,超声示右侧胸腔积液。2024年2月复查示HCL复发,予维莫非尼联合利妥昔单抗治疗,迅速达到完全缓解并不伴微小残留病。本病例可为复发性HCL的治疗提供参考。

     

    Abstract: Hairy cell leukemia(HCL) is a rare malignant hematological tumor. This article presents the diagnosis and treatment of a patient with recurrent HCL. This patient, a 51-year-old female, was diagnosed with HCL in June 2013 and subsequently received monotherapy with cladribine. Post-treatment evaluation indicated a partial remission. In November 2023, she experienced chest tightness and shortness of breath with ultrasound revealing a right-sided pleural effusion. A follow-up examination in February 2024 confirmed the relapse of HCL. She was then treated with a combination of vemurafenib and rituximab, which resulted in a rapid complete remission without minimal residual disease. This case provides valuable insights into the management of recurrent HCL.

     

/

返回文章
返回